Trial Profile
Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Biomarker; Pharmacodynamics
- Acronyms ASSESS
- 03 Aug 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Sep 2013 New source identified and integrated (University Hospital Medical Information Network - Japan; UMIN000003222).
- 06 Apr 2010 Trial acronym (ASSESS), long name and actual initiation date (Apr 2010) added as reported by ClinicalTrials.gov.